slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 71,641-71,670
Pages 3,683
Rows per page 30
Component
71,641-71,670 of 110,471
100
The slide uses a direct quote to undermine the value proposition of the drug Vykat by highlighting the availability of cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
101
The slide uses direct quotes to expose contradictions in the drug's adoption and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
105
The slide uses a direct comparison of drug mechanisms to challenge the target company's safety claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
112
The slide uses a combination of narrative accusation and technical definitions to frame the company's data as obfuscated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
138
The slide uses a list of 6 risk factors to build a medical case for why the drug's side effects are particularly dangerous for this specific patient group.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
142
The slide uses medical definitions to frame the clinical trial results as evidence of adverse effects (edema) related to the drug DCCR.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
144
The slide uses a medical illustration to show the impact of fluid retention on heart chambers (diastolic vs systolic).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
145
The slide uses red annotations to re-interpret the company's original chart data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
146
The slide uses a technical explanation of DEXA limitations to undermine the company's reported clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
153
The slide uses a combination of medical argumentation and cited research conclusions to highlight the risks of a specific drug regimen.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
186
The slide uses a Q&A format to present evidence of potential trial manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
205
The slide uses annotated charts to highlight alleged data manipulation in a clinical study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
209
Uses a pharmacokinetic chart to illustrate the mechanism of XR vs immediate release to debunk the necessity of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
210
The slide uses two charts to illustrate why XR is ineffective for this specific drug profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
215
The slide uses a Q&A format to validate the thesis that MDCalc is a key driver for off-label drug substitution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
230
The slide uses highlighted text to emphasize key criticisms (soft endpoints, cherry-picking, safety signals).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
235
The slide uses Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
278
The slide uses a Q&A format to highlight negative expert sentiment regarding commercial viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
284
The slide uses a Q&A transcript format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
285
The slide uses a Q&A format to present expert opinion as evidence of safety risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
292
The slide uses a Q&A format to highlight allegations of data manipulation and lack of clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
293
The slide uses direct quotes and Q&A transcripts to undermine the credibility of the drug's launch prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
304
The slide uses a 'villain_critique' structure to undermine a competitor's clinical trial results by citing an expert's negative testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
305
The slide uses direct quotes from a trial investigator to undermine the drug's market potential and clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
310
The slide uses bolding and highlighting to emphasize negative feedback from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
311
The slide uses a Q&A format to document expert testimony regarding trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
315
Includes verbatim Q&A transcripts highlighting the investigator's passive approach to patient recruitment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
319
The slide uses a Q&A transcript format to expose flaws in clinical trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit